发明名称 COMBINED ANTICANCER DRUG SENSITIVITY-DETERMINING MARKER
摘要 <p>To provide an anti-cancer agent sensitivity determination marker, which marker can determine whether or not the patient has a therapeutic response to the anti-cancer agent, and novel cancer therapeutic means employing the marker. The anti-cancer agent sensitivity determination marker, the anti-cancer agent including oxaliplatin or a salt thereof and fluorouracil or a salt thereof, contains one or more substances selected from among an amino-acid-metabolism-related substance, a nucleic-acid-metabolism-related substance, a substance in the pentose phosphate pathway, a substance in the glycolytic pathway, a substance in the TCA cycle, a polyamine-metabolism-related substance, 7,8-dihydrobiopterin, 6-phosphogluconic acid, butyric acid, triethanolamine, 1-methylnicotinamide, NADH, NAD + , and a substance involved in the metabolism of any of these substances.</p>
申请公布号 EP2818870(A1) 申请公布日期 2014.12.31
申请号 EP20130752246 申请日期 2013.02.22
申请人 KEIO UNIVERSITY;KABUSHIKI KAISHA YAKULT HONSHA 发明人 TANIGAWARA, YUSUKE;NISHIMUTA, AKITO;TSUZAKI, JUNYA;TAKAHASHI, HIROYUKI
分类号 A61K31/513;A61K31/555;A61K45/00;A61K45/06;A61K47/18;A61K47/26;A61P43/00;G01N33/15;G01N33/50;G01N33/574 主分类号 A61K31/513
代理机构 代理人
主权项
地址